Inmune Bio (INMB) Enterprise Value (2017 - 2026)
Inmune Bio (INMB) posted Enterprise Value of -$21.4 million for Q1 2026, up 13.71% sequentially from -$24.8 million in Q4 2025, and down 10.45% YoY from -$23.9 million in Q1 2025.
Inmune Bio (INMB) Enterprise Value (2017 - 2026) Analysis & Trends
Inmune Bio has reported Enterprise Value for 10 years, with the latest figure at -$21.4 million in Q1 2026.
- Quarterly Enterprise Value fell 10.45% year-over-year to -$21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.4 million (down 10.45% YoY) and the FY2025 annual result came in at -$24.8 million, down 18.3% from the prior year.
- Enterprise Value rose to -$21.4 million in Q1 2026 per INMB's latest filing, from -$24.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$19.3 million in Q1 2025 and troughed at -$66.7 million in Q1 2022.
- A 5-year average of -$38.3 million and a median of -$33.6 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 51.1% in 2022, then soared 49.02% in 2024.
- Over 5 years, Enterprise Value stood at -$52.2 million in 2022, then surged by 31.26% to -$35.8 million in 2023, then surged by 41.64% to -$20.9 million in 2024, then declined by 18.3% to -$24.8 million in 2025, then gained by 13.71% to -$21.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$21.4 million, -$24.8 million, and -$27.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -18.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.41 Mn |
| Mar 31, 2026 | -21.36 Mn |
| Dec 31, 2025 | -24.75 Mn |
| Sep 30, 2025 | -27.73 Mn |
| Jun 30, 2025 | -33.37 Mn |
| Mar 31, 2025 | -19.34 Mn |
| Dec 31, 2024 | -20.92 Mn |
| Sep 30, 2024 | -33.55 Mn |
| Jun 30, 2024 | -31.07 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Dec 31, 2023 | -35.85 Mn |
| Sep 30, 2023 | -41.81 Mn |
| Jun 30, 2023 | -47.83 Mn |
| Mar 31, 2023 | -51.00 Mn |
| Dec 31, 2022 | -52.15 Mn |
| Sep 30, 2022 | -57.41 Mn |
| Jun 30, 2022 | -59.72 Mn |
| Mar 31, 2022 | -66.73 Mn |
| Dec 31, 2021 | -74.81 Mn |
| Sep 30, 2021 | -84.47 Mn |